Contact this trialFirst, we need to learn more about you.
MAPK Inhibitor
Belvarafenib + Cobimetinib/Nivolumab for Melanoma
Recruiting1 awardPhase 1
Nashville, Tennessee
This trial tests belvarafenib alone and in combination with other drugs for advanced melanoma patients who haven't responded to previous treatments. The drugs aim to stop cancer growth or help the immune system fight the cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service